Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | STK17B | O94768 | 3/20 | 1.00 |
| ▸ | MAOA | P21397 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 2/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 1.00 |
| ▸ | PSMD14 | O00487 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ALPL | P05186 | 1/20 | 1.00 |
| ▸ | ALPI | P09923 | 1/20 | 1.00 |
| ▸ | ALPG | P10696 | 1/20 | 1.00 |
| ▸ | CDK4 | P11802 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuretin SCHEMBL30214394 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| Sulfuretin SCHEMBL30214408 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| Sulfuretin SCHEMBL634007 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| Sulfuretin SCHEMBL8346701 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| Sulfuretin SCHEMBL29545005 | 1.00 | MEN1 (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| SCHEMBL30337058 | 0.89 | STK17B (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| SCHEMBL5707753 | 0.88 | TYR (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| SCHEMBL29435856 | 0.88 | TYR (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| SCHEMBL30214422 | 0.88 | TYR (1.00) | MEN1KMT2ARECQLSTK17BMAOA | |
| SCHEMBL6964950 | 0.88 | MEN1 (0.78) | MEN1KMT2ARECQLSTK17BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713561-B1 | COMBINATION OF BUTEIN, ISOLIQUIRITIGENIN AND SULFURETIN, AND ITS USE FOR THE TREATMENT OF DIABETES AND ASSOCIATED DISORDERS | OTAGO INNOVATION LTD (NZ) | 2026-05-06 | — | — | EP | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4583856-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | Native Code Bio, LLC (US) | 2025-07-16 | — | — | EP | claimed |
| US-20250064773-A1 | TARGETING ERO1 ALPHA WITH AURONE DERIVATIVES | West Virginia University Board of Governors on behalf of West Virginia University (US) | 2025-02-27 | — | — | US | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024054688-A2 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO, LLC (US) | 2024-03-14 | — | — | WO | claimed |
| US-11738001-B2 | Pharmaceutical combinations and methods for the treatment of diabetes and associated disorders | OTAGO INNOVATION LIMITED (NZ) | 2023-08-29 | — | — | US | claimed |
| WO-2023114761-A2 | TARGETING ERO1 ALPHA WITH AURONE DERIVATIVES | West Virginia University Board of Governors on behalf of West Virginia University (US) | 2023-06-22 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| CN-1653083-A | Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation | NICOX SA (FR) | 2005-08-10 | — | — | CN | claimed |
| US-6872771-B1 | Tire with rubber containing flavone | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2005-03-29 | — | — | US | claimed |
| WO-2005011671-A1 | USE OF FLAVONOIDS FOR PREVENTING AND TREATING GASTRITIS AND GASTRIC ULCER | LIFETREE BIOTECH CO., LTD. (KR) | 2005-02-10 | — | — | WO | claimed |
| EP-1504020-A2 | DEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF ACUTE DYSFUNCTIONS OF PORTAL AND HEPATIC VENOUS CIRCULATION | Nicox S.A. (FR) | 2005-02-09 | — | — | EP | claimed |
| WO-2004043443-A2 | DRUGS FOR SEXUAL DYSFUNCTIONS | NICOX S.A. (FR) | 2004-05-27 | — | — | WO | claimed |
| WO-2004002471-A1 | COMPOSITION COMPRISING PHENOLIC COMPOUND FOR PREVENTING AND TREATING LIVER CIRRHOSIS | LIFETREE BIOTECH CO., LTD. (KR) | 2004-01-08 | — | — | WO | claimed |
| WO-2003095471-A2 | DEOXYCHOLIC ACID DERIVATIVES FOR THE TREATMENT OF ACUTE DYSFUNCTIONS OF PORTAL AND HEPATIC VENOUS CIRCULATION | NICOX S.A. (IT) | 2003-11-20 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-6221358-B1 | Treating or preventing hangover, alcoholic gastritis and alcohol-induced liver damage; extract contains fustin, fisetin, sulfuretin and butein | FORESTRY RESEARCH INSTITUTE (KR) | 2001-04-24 | — | — | US | claimed |
| WO-1998027970-A2 | TREATMENT OF DISEASES OR PREVENTION OF CELLULAR DAMAGE CAUSED BY OXYGEN-CONTAINING FREE RADICALS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1998-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738001-B2 | Pharmaceutical combinations and methods for the treatment of diabetes and associated disorders | IAPP, SLC5A2, PCSK9 | MEN1 1522/4885KMT2A 3474/4885RECQL 563/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | MEN1 1711/4885KMT2A 4742/4885RECQL 2324/4885 |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | HMBS, SNCA, PYGB | MEN1 2138/4885KMT2A 1583/4885RECQL 3569/4885 |
| US-20250064773-A1 | TARGETING ERO1 ALPHA WITH AURONE DERIVATIVES | ERO1A, HSP90B1, XPO1 | MEN1 2374/4885KMT2A 4333/4885RECQL 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.